Home » Stocks » IDEAYA Biosciences

IDEAYA Biosciences, Inc. (IDYA)

Stock Price: $12.77 USD -0.89 (-6.52%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 370.69M
Revenue (ttm) n/a
Net Income (ttm) -46.18M
Shares Out 29.03M
EPS (ttm) -2.26
PE Ratio n/a
Forward PE 4.65
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $12.77
Previous Close $13.66
Change ($) -0.89
Change (%) -6.52%
Day's Open 13.84
Day's Range 12.34 - 13.84
Day's Volume 1,444,271
52-Week Range 2.95 - 19.97

More Stats

Market Cap 370.69M
Enterprise Value 206.39M
Earnings Date (est) Nov 11, 2020
Ex-Dividend Date n/a
Shares Outstanding 29.03M
Float 16.37M
EPS (basic) -1.93
EPS (diluted) -2.26
FCF / Share -2.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 686,959
Short Ratio 4.31
Short % of Float 4.20%
Beta n/a
PE Ratio n/a
Forward PE 4.65
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.30
Revenue n/a
Operating Income -48.01M
Net Income -46.18M
Free Cash Flow -42.77M
Net Cash 164.30M
Net Cash / Share 5.66
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -18.88%
ROE -31.56%
ROIC -69.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 1
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(89.66% upside)
Current: $12.77
Target: 24.22
*Average 12-month price target from 9 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-44.27-36.42-14.44
Net Income-41.98-34.35-11.86
Shares Outstanding12.500.960.70
Earnings Per Share-3.36-35.92-17.06
Operating Cash Flow-39.31-27.62-12.22
Capital Expenditures-1.35-1.71-1.76
Free Cash Flow-40.67-29.33-13.98
Cash & Equivalents99.0690.0713.23
Total Debt6.77--
Net Cash / Debt92.2990.0713.23
Book Value100-48.95-15.74
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name IDEAYA Biosciences, Inc.
Country United States
Employees 46
CEO Yujiro S. Hata

Stock Information

Ticker Symbol IDYA
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: IDYA
IPO Date May 23, 2019


IDEAYA Biosciences, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase 1/2 clinical trial for genetically-defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting MAT2A for solid tumors with MTAP deletions; Pol-theta in tumors with homologous recombination deficiency, including BRCA mutations; PARG in tumors with BRCA2 mutations in base excision repair; and WRN in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase 1/2 study in metastatic uveal melanoma and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was founded in 2015 and is headquartered in South San Francisco, California.